INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Boston Scientific Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its revenue outlook and market competition [1]. Company Overview - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [1]. Class Action Details - The class action lawsuit, titled Troike v. Boston Scientific Corporation, includes investors who purchased Boston Scientific common stock between July 23, 2025, and February 3, 2026, with a deadline of May 4, 2026, to seek lead plaintiff status [1]. - Allegations include that Boston Scientific executives made false statements about the company's revenue projections and downplayed risks from market competition and macroeconomic factors [1]. Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, showing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year prior [1]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, up from $1.853 billion or $1.25 per share the previous year, with adjusted EPS of $3.06 compared to $2.51 a year ago [1]. - The company's stock price fell over 17% following the announcement of these results, which did not meet the company's guidance range of $0.48 to $0.52 per share [1].